Dry wound dressing and drug delivery system

Abstract

Dry dressings incorporate drug-delivery systems for anti-infective agents, growth factors, fibronectin or other substances to enhance tissue healing. A pharmaceutical composition includes hyaluronate polyvinylpyrrolidone (PVP), maltodextrin, and hydroxyethylcellulose and glycerin in the form of a membranous, wafer-like material after being freeze-dried.

1. A lyophilized pharmaceutical composition comprising hyaluronate, polyvinylpyrrolidone (PVP), maltodextrin, hydroxyethylcellulose, and glycerin in the form of a membranous, wafer material after being lyophilized. 
     
     
       2. The pharmaceutical composition of  claim 1  further comprising one or more chemotherapeutic agents. 
     
     
       3. The pharmaceutical composition of  claim 1  further comprising cFN. 
     
     
       4. The pharmaceutical composition of  claim 1  further comprising growth factors. 
     
     
       5. The pharmaceutical composition of  claim 1  further comprising an antimicrobial agent. 
     
     
       6. A dry wound dressing comprising the pharmaceutical composition of  claim 1 . 
     
     
       7. The dry wound dressing of  claim 6  wherein the wounds are selected from the group consisting of abrasions, ulcers, burns, traumatic and surgical wounds. 
     
     
       8. The dry wound dressing of  claim 6  in the form of an adhesive strip. 
     
     
       9. A method to cover wounds, the method comprising
 (a) selecting a wound, from the group consisting of oral sores, mucositis or stomatitis resulting from chemotherapy, radiation therapy, dental braces, aphthous ulcers, and stem cell therapy, and 
 (b) applying the dry wound dressing of  claim 6  to the wound. 
 
     
     
       10. The dry wound dressing of  claim 7  wherein ulcers are selected from the group consisting of chronic ulcers, diabetic ulcers, decubitus ulcers, and venous stasis ulcers. 
     
     
       11. The pharmaceutical composition of  claim 3  used to treat chronic ulcers, stomatitis, or other wounds that would benefit from the healing properties of fibronectin. 
     
     
       12. A method of decreasing the incidence of post-operative adhesions, the method comprising:
 (a) obtaining the pharmaceutical composition of  claim 1 ; and 
 (b) applying the pharmaceutical composition to the adhesion. 
 
     
     
       13. A method to deliver fibronectin to a wound, the method comprising:
 (a) obtaining a concentrated solution of fibronectin; 
 (b) combining the fibronectin with the dry wound dressing of  claim 6 ; and 
 (c) applying the dressing to the wound. 
 
     
     
       14. A lophilized composition comprising before lyophilization from about 0.01% to about 5% by weight/volume of hyaluronic acid, or a pharmaceutically acceptable salt thereof, having a molecular weight from about 500,000 daltons to about 2.2 million daltons; from about 0.04% to about 15% by weight/volume of a K60 to K100 polyvinylpyrrolidone, resulting in a membranous, wafer material lyophilization. 
     
     
       15. The composition of  claim 14 , further optionally comprising an agent that enhances tissue healing, the agent selected from the group consisting of an antibacterial agent, disinfectant agent, antifungal agent, analgesic, anti-inflammatory, emollient, a local anesthetic, and combinations thereof. 
     
     
       16. A lyophilized composition for treating inflammation in a patient comprising before lyophilization an effective amount of (i) from about 0.01 to about 5% by weight/volume of hyaluronic acid, or a pharmaceutically acceptable salt thereof, having a molecular weight from about 500,000 to about 2.2 million daltons; (ii) from about 0.04% to about 15% by weight/volume of a K60 to K100 polyvinylpyrrolidone; and (iii) from about 86 to about 98% water, resulting in a membranous, wafer material lyophilization. 
     
     
       17. The composition of  claim 16  wherein the inflammation is in the oral cavity of the patient. 
     
     
       18. The composition of  claim 16  wherein the patient has oral mucositis. 
     
     
       19. A lyophilized composition for treating mucositis in a patient comprising an effective amount of hyaluronic acid or a pharmaceutically acceptable salt thereof; and polyvinylpyrrolidone in the form of a membranous, wafer material. 
     
     
       20. The composition of  claim 1  for treating pain resulting from oral surgery.